202 related articles for article (PubMed ID: 22920753)
21. NDRG2 contributes to cisplatin sensitivity through modulation of BAK-to-Mcl-1 ratio.
Park S; Oh SS; Lee KW; Lee YK; Kim NY; Kim JH; Yoo J; Kim KD
Cell Death Dis; 2018 Jan; 9(2):30. PubMed ID: 29348517
[TBL] [Abstract][Full Text] [Related]
22. miR-24-2 controls H2AFX expression regardless of gene copy number alteration and induces apoptosis by targeting antiapoptotic gene BCL-2: a potential for therapeutic intervention.
Srivastava N; Manvati S; Srivastava A; Pal R; Kalaiarasan P; Chattopadhyay S; Gochhait S; Dua R; Bamezai RN
Breast Cancer Res; 2011 Apr; 13(2):R39. PubMed ID: 21463514
[TBL] [Abstract][Full Text] [Related]
23. NDRG2 mRNA levels and miR-28-5p and miR-650 activity in chronic lymphocytic leukemia.
Yang YQ; Tian T; Zhu HY; Liang JH; Wu W; Wu JZ; Xia Y; Wang L; Fan L; Li JY; Xu W
BMC Cancer; 2018 Oct; 18(1):1009. PubMed ID: 30348117
[TBL] [Abstract][Full Text] [Related]
24. MiR-122 increases sensitivity of drug-resistant BEL-7402/5-FU cells to 5-fluorouracil via down-regulation of bcl-2 family proteins.
Yin J; Tang HF; Xiang Q; Yu J; Yang XY; Hu N; Lei XY
Pharmazie; 2011 Dec; 66(12):975-81. PubMed ID: 22312705
[TBL] [Abstract][Full Text] [Related]
25. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
26. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma.
Zhang H; Li M; Han Y; Hong L; Gong T; Sun L; Zheng X
Dig Dis Sci; 2010 Sep; 55(9):2545-51. PubMed ID: 19960259
[TBL] [Abstract][Full Text] [Related]
27. RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression.
Cho HJ; Baek KE; Park SM; Kim IK; Nam IK; Choi YL; Park SH; Im MJ; Choi J; Ryu J; Kim JW; Lee CW; Kang SS; Yoo J
Cancer Lett; 2011 Dec; 311(1):48-56. PubMed ID: 21752536
[TBL] [Abstract][Full Text] [Related]
28. Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin.
Feng Y; Zou W; Hu C; Li G; Zhou S; He Y; Ma F; Deng C; Sun L
Arch Biochem Biophys; 2017 Jun; 623-624():20-30. PubMed ID: 28495512
[TBL] [Abstract][Full Text] [Related]
29. Effects of microRNA-1271 on ovarian cancer via inhibition of epithelial-mesenchymal transition and cisplatin resistance.
Chen Y; Wang L; Zhou J
J Obstet Gynaecol Res; 2019 Nov; 45(11):2243-2254. PubMed ID: 31411791
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of cisplatin sensitivity of cisplatin-resistant human cervical carcinoma cells by bryostatin 1.
Mohanty S; Huang J; Basu A
Clin Cancer Res; 2005 Sep; 11(18):6730-7. PubMed ID: 16166454
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-497 induces cell apoptosis by negatively regulating Bcl-2 protein expression at the posttranscriptional level in human breast cancer.
Wei C; Luo Q; Sun X; Li D; Song H; Li X; Song J; Hua K; Fang L
Int J Clin Exp Pathol; 2015; 8(7):7729-39. PubMed ID: 26339338
[TBL] [Abstract][Full Text] [Related]
32. Downregulation of Mcl-1 synergizes the apoptotic response to combined treatment with cisplatin and a novel fiber chimeric oncolytic adenovirus.
You L; Wang Y; Jin Y; Qian W
Oncol Rep; 2012 Apr; 27(4):971-8. PubMed ID: 22266706
[TBL] [Abstract][Full Text] [Related]
33. MiR-26a enhances the sensitivity of gastric cancer cells to cisplatin by targeting NRAS and E2F2.
Wen L; Cheng F; Zhou Y; Yin C
Saudi J Gastroenterol; 2015; 21(5):313-9. PubMed ID: 26458859
[TBL] [Abstract][Full Text] [Related]
34. Long Noncoding RNA GAS5, Which Acts as a Tumor Suppressor via microRNA 21, Regulates Cisplatin Resistance Expression in Cervical Cancer.
Wen Q; Liu Y; Lyu H; Xu X; Wu Q; Liu N; Yin Q; Li J; Sheng X
Int J Gynecol Cancer; 2017 Jul; 27(6):1096-1108. PubMed ID: 28472815
[TBL] [Abstract][Full Text] [Related]
35. Suppression of long noncoding RNA NCK1-AS1 increases chemosensitivity to cisplatin in cervical cancer.
Zhang WY; Liu YJ; He Y; Chen P
J Cell Physiol; 2019 Apr; 234(4):4302-4313. PubMed ID: 30221354
[TBL] [Abstract][Full Text] [Related]
36. TTP mediates cisplatin-induced apoptosis of head and neck cancer cells by down-regulating the expression of Bcl-2.
Park SB; Lee JH; Jeong WW; Kim YH; Cha HJ; Joe Y; Chung HT; Cho WJ; Do JW; Lee BJ; Park JW; Ko BK
J Chemother; 2015 Jun; 27(3):174-80. PubMed ID: 25604244
[TBL] [Abstract][Full Text] [Related]
37. SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines.
Chen X; Xiong D; Ye L; Yang H; Mei S; Wu J; Chen S; Mi R
Cancer Chemother Pharmacol; 2019 Apr; 83(4):603-613. PubMed ID: 30627777
[TBL] [Abstract][Full Text] [Related]
38. Ganoderic acid A/DM-induced NDRG2 over-expression suppresses high-grade meningioma growth.
Das A; Alshareef M; Henderson F; Martinez Santos JL; Vandergrift WA; Lindhorst SM; Varma AK; Infinger L; Patel SJ; Cachia D
Clin Transl Oncol; 2020 Jul; 22(7):1138-1145. PubMed ID: 31732915
[TBL] [Abstract][Full Text] [Related]
39. Lycopene sensitizes the cervical cancer cells to cisplatin via targeting nuclear factor- kappa B (NF-κB) pathway.
Aktepe OH; Şahin TK; Güner G; Arik Z; Yalçin Ş
Turk J Med Sci; 2021 Feb; 51(1):368-374. PubMed ID: 32718121
[TBL] [Abstract][Full Text] [Related]
40. Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy.
Sharma H; Sen S; Lo Muzio L; Mariggiò A; Singh N
Cancer Biol Ther; 2005 Jul; 4(7):720-7. PubMed ID: 15917659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
